ID

34573

Beskrivning

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02240238

Länk

https://clinicaltrials.gov/show/NCT02240238

Nyckelord

  1. 2019-01-19 2019-01-19 -
  2. 2020-09-28 2020-09-28 -
  3. 2020-10-01 2020-10-01 -
Rättsinnehavare

see on clinicaltrials.gov

Uppladdad den

19 januari 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Solid Tumors NCT02240238

Eligibility Solid Tumors NCT02240238

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
(part 1 only) have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy.
Beskrivning

ID.1

Datatyp

boolean

(part 2 only) have histologically or cytologically confirmed diagnosis of stage iiib or iv nsclc and have received 1 or 2 lines of prior chemotherapy or targeted therapy for stage iiib or iv nsclc (second- or third-line).
Beskrivning

ID.2

Datatyp

boolean

have measurable disease per response evaluation criteria in solid tumors (recist) version 1.1.
Beskrivning

ID.3

Datatyp

boolean

eastern cooperative oncology group (ecog) performance status of 0 to 1
Beskrivning

ID.4

Datatyp

boolean

have adequate bone marrow reserve, liver function, and renal function
Beskrivning

ID.5

Datatyp

boolean

Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
have received prior platinum therapy in the past 3 months
Beskrivning

ID.6

Datatyp

boolean

have received prior cisplatin and gemcitabine concomitantly within the last 6 months or are refractory to cisplatin and gemcitabine.
Beskrivning

ID.7

Datatyp

boolean

unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment
Beskrivning

ID.8

Datatyp

boolean

pregnant or breast feeding
Beskrivning

ID.9

Datatyp

boolean

Similar models

Eligibility Solid Tumors NCT02240238

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
(part 1 only) have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy.
boolean
ID.2
Item
(part 2 only) have histologically or cytologically confirmed diagnosis of stage iiib or iv nsclc and have received 1 or 2 lines of prior chemotherapy or targeted therapy for stage iiib or iv nsclc (second- or third-line).
boolean
ID.3
Item
have measurable disease per response evaluation criteria in solid tumors (recist) version 1.1.
boolean
ID.4
Item
eastern cooperative oncology group (ecog) performance status of 0 to 1
boolean
ID.5
Item
have adequate bone marrow reserve, liver function, and renal function
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
have received prior platinum therapy in the past 3 months
boolean
ID.7
Item
have received prior cisplatin and gemcitabine concomitantly within the last 6 months or are refractory to cisplatin and gemcitabine.
boolean
ID.8
Item
unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment
boolean
ID.9
Item
pregnant or breast feeding
boolean

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial